Is it safe to switch from intravenous immunoglobulin to subcutaneous immunoglobulin in patients with common variable immunodeficiency and autoimmune thrombocytopenia?
<p><strong>Background:</strong> A significant amount of common variable immunodeficiency (CVID) patients manifest with autoimmunity. Particularly, autoimmune thrombocytopenia (AITP) is commonly seen. Intravenous immunoglobulins (IVIG) are an established treatment option for both, C...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Journal article |
| Published: |
Frontiers Media
2018
|